A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate
← catalyst calendarSponsored by Daiichi Sankyo (industry) · 4568.T — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
70actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-24 | actual | When the study began enrolling |
| Primary completion | 2025-06-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-12 | actual | The whole study's end, after follow-up |
| First posted | 2025-01-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-08-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Subjects
Interventions
- Drug: Quizartinib — also filed as VANFLYTA®
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFChange in Heart Rate
measured Day 1 and Day 2
Permalink · 4568.T's whole pipeline · Catalyst calendar · Every registered study · What changed